Literature DB >> 23503456

The mathematics of drug dose individualization should be built with random-effects linear models.

Francisco J Diaz, Jose de Leon.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23503456     DOI： 10.1097/FTD.0b013e318283e3c6

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


× No keyword cloud information.
  6 in total

1.  Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.

Authors:  Francisco J Diaz; Michel J Berg; Ron Krebill; Timothy Welty; Barry E Gidal; Rita Alloway; Michael Privitera
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

2.  Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models.

Authors:  Francisco J Diaz
Journal:  Stat Med       Date:  2016-06-20       Impact factor: 2.373

3.  A graphical approach to assess the goodness-of-fit of random-effects linear models when the goal is to measure individual benefits of medical treatments in severely ill patients.

Authors:  Zhiwen Wang; Francisco J Diaz
Journal:  BMC Med Res Methodol       Date:  2020-07-20       Impact factor: 4.615

4.  The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial.

Authors:  Francisco J Diaz; Richard C Josiassen; Jose de Leon
Journal:  J Clin Psychopharmacol       Date:  2018-10       Impact factor: 3.153

5.  Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users.

Authors:  Xuan Zhang; Jose de Leon; Benedicto Crespo-Facorro; Francisco J Diaz
Journal:  J Biopharm Stat       Date:  2020-06-08       Impact factor: 1.503

6.  "De-Shrinking" EBEs: The Solution for Bayesian Therapeutic Drug Monitoring.

Authors:  Sarah Baklouti; Peggy Gandia; Didier Concordet
Journal:  Clin Pharmacokinet       Date:  2022-02-04       Impact factor: 5.577
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.